Testing three drug combo for untreated CLL or CLL-related cancer
Treatments studied
Part of Blood & lymphatic, Cancer clinical trials.
This Phase 2 study tests pirtobrutinib plus venetoclax plus obinutuzumab in people with untreated chronic lymphocytic leukemia (CLL) or CLL-related Richter transformation (RT). The goal is to see if this “triplet” combination works better and is safe enough to control the disease.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 or older, and you have CLL/SLL that needs treatment (or you have Richter transformation from CLL).
- You can perform daily activities pretty well (ECOG 0–2).
- Your liver and kidney lab tests are within required limits.
- Your blood counts are strong enough (platelets, hemoglobin, and neutrophils meet minimums).
- You can swallow the study tablets and can come to visits and do frequent blood tests as required.
- If you could become pregnant, you must use effective birth control and have a negative pregnancy test; men with partners who could become pregnant must also use effective contraception.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests three drugs—roginolisib, venetoclax, and rituximab—for people with CLL that has come back or not responded after at least two prior treatments, including a BTK inhibitor. The goal is to see if this combination is safe and effective.
This trial tests a combination of three drugs (pirtobrutinib, venetoclax, and obinutuzumab) given for a limited time to people whose CLL/SLL has come back after prior treatment. The goal is to see if this combination can control the cancer and possibly allow a treatment-free period.
This trial tests a three-drug combination for people who have not yet had treatment for chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). It aims to improve outcomes with a targeted, mostly oral regimen.
This trial tests a new combination of an oral targeted therapy and a short course of chemotherapy for patients with previously untreated chronic lymphocytic leukemia (CLL). The goal is to control the disease and improve outcomes.
This trial tests two oral targeted drugs—pirtobrutinib and venetoclax—for people with CLL or SLL whose disease has continued to grow despite taking a BTK inhibitor (such as ibrutinib, acalabrutinib, or zanubrutinib). The goal is to see if this combination can control the cancer when a BTK inhibitor alone is no longer working.
This trial tests a new combination of drugs (sonrotoclax plus zanubrutinib) against another standard combination (venetoclax plus acalabrutinib) for people with chronic lymphocytic leukemia (CLL) who have not had treatment before. The goal is to see which combination works better.
Hear when a new Leukemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.